Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Nurix Therapeutics, Inc. reports developments as a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for oncology and autoimmune and inflammatory diseases. News commonly centers on bexobrutideg (NX-5948), a Bruton’s tyrosine kinase degrader, including clinical data in chronic lymphocytic leukemia, small lymphocytic lymphoma and Waldenström macroglobulinemia, as well as updates tied to the DAYBreak development program.
Company updates also cover Nurix’s DEL-AI discovery platform, preclinical degrader programs against targets such as pan-mutant BRAF, CBL-B and Aurora kinase A, and partnered inflammation and immunology programs involving IRAK4 and STAT6 degraders. Recurring announcements include financial results, corporate presentations, scientific meeting data, pipeline progress, capital actions and board or governance changes.
Nurix Therapeutics (NASDAQ: NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's CEO, Dr. Arthur T. Sands, and CFO, Hans van Houte, will engage in a fireside chat on June 4, 2025, at 3:45 p.m. ET in New York. The presentation will be available through a live webcast on Nurix's website, with the recording remaining accessible for 30 days following the event.
Nurix Therapeutics (NRIX) has granted inducement awards to 13 new employees on May 13, 2025, as part of their 2024 Equity Inducement Plan. The awards include stock options to purchase 87,950 shares of common stock at $9.73 per share and restricted stock unit awards (RSUs) for 60,050 shares.
The stock options will vest over 4 years, with 25% vesting after one year and the remainder vesting monthly. The RSUs will also vest over 4 years, with 25% vesting after one year and the remainder vesting quarterly. Both awards are subject to continued employment.
Nurix Therapeutics (NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines, announced its participation in the upcoming RBC Capital Markets Global Healthcare Conference. The company's Chief Financial Officer Hans van Houte and Chief Business Officer Jason Kantor, Ph.D., will engage in a fireside chat on Wednesday, May 21, 2025, at 2:05 p.m. ET in New York, NY. The presentation will be available through a live webcast on Nurix's website in the Investors section, with the recording remaining accessible for 30 days following the event.
Nurix Therapeutics (NRIX) announced upcoming presentations of clinical data for their drug bexobrutideg (NX-5948) at two major scientific conferences in June 2025. The data comes from ongoing Phase 1a/b clinical trials studying the drug's effects on patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia.
The presentations will take place at the European Hematology Association Congress (EHA 2025) in Milan and the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano. The data will be featured in two posters at EHA 2025 and in both an oral presentation and poster at 18-ICML, focusing on bexobrutideg's clinical responses and safety profile as a novel Bruton's tyrosine kinase (BTK) degrader.
Nurix Therapeutics unveiled groundbreaking data at the AACR 2025 Annual Meeting showcasing their innovative DEL-AI platform, which combines DNA-encoded libraries with machine learning to accelerate drug discovery.
The company's DEL Foundation Model, developed in collaboration with Loka and supported by Amazon Web Services, demonstrates remarkable capabilities in:
- Accurately predicting novel drug binders for therapeutic targets
- Working with as little as 50% amino acid sequence similarity
- Identifying potential treatments for previously "undruggable" targets
- Inferring binders from chemical space outside training data
This AI-powered platform represents a significant advancement in drug discovery, potentially streamlining the identification of small molecule drugs, protein degraders, and molecular glues. The technology leverages Nurix's extensive database of over five billion unique DEL compounds screened against hundreds of disease targets and E3 ligase proteins.
The presentation, titled "DEL-AI: Proteome-wide in silico screening of multi-billion compound libraries using machine learning foundation models," validates the platform's ability to perform virtual DEL experiments and accurately predict experimental results.
Nurix Therapeutics (NRIX) presented positive preclinical data at AACR 2025 for multiple orally available, brain-penetrant protein degraders targeting three oncology targets. Bexobrutideg, their lead BTK degrader, demonstrated exceptional efficiency by degrading approximately 10,000 BTK copies per hour at clinically relevant concentrations.
The company showcased NRX-0305, a BRAF degrader effective across all three BRAF mutation classes while sparing healthy cells. It showed superior anti-tumor efficacy in resistant tumors compared to competitor CFT1946 and demonstrated effectiveness in combination with MEKi.
Additionally, Nurix presented data on NRX-4972, an orally bioavailable Aurora A kinase degrader developed in collaboration with Alex's Lemonade Stand Foundation. This degrader showed significant efficacy in neuroblastoma models, inducing DNA damage, apoptosis, and G2/M arrest more effectively than traditional inhibitors.
Nurix Therapeutics (NRIX) announced FDA clearance of their IND application for GS-6791/NX-0479, a novel IRAK4 degrader developed for inflammatory conditions. The Phase 1 trial is set to begin in Q2 2025, focusing on single and multiple ascending dose studies in healthy volunteers.
The development triggers a $5 million milestone payment from collaboration partner Gilead Sciences, bringing total payments under their 2019 agreement to $135 million. Nurix remains eligible for additional $420 million in milestones plus potential royalties.
GS-6791/NX-0479 has shown promising preclinical results, demonstrating rapid IRAK4 degradation across multiple human cell types and robust efficacy in arthritis models. The drug targets inflammatory conditions including rheumatoid arthritis and atopic dermatitis. Nurix retains the option to co-develop and co-detail in the US, with a 50/50 split of profits and losses.